Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Release Date: August 30, 2024

Expiration Date: September 6, 2026

Activity Overview

Recent advances in prostate cancer screening have addressed the limitations of prostate-specific antigen (PSA) testing, which has a lack of specificity and a risk of overdiagnosis and overtreatment. New biomarker tests offer greater diagnostic accuracy by targeting specific biomarkers and potentially reducing unnecessary biopsies.

This educational activity aims to update health care professionals on advances in prostate cancer screening with the goal of improving prostate cancer risk assessment and decision-making and reducing unnecessary treatments. The Medical Crossfire format facilitates discussion in the context of evidence-based presentations, highlighting the current challenges and opportunities in the field and providing practical advice for implementing best practices.

Target Audience

This educational activity is directed toward urologists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in diagnosing patients for prostate cancer will be invited to participate as well.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the inherent limitations of PSA screening in terms of specificity and prostate biopsies
• Differentiate between adjunctive tests for prostate cancer assessment with respect to their clinical effectiveness in monitoring and active surveillance
• Assess the latest clinical data regarding the role of adjunctive tests in the detection of high-grade prostate cancers
• Incorporate adjunctive tests into clinical practice for prostate cancer risk assessment based upon the most up-to-date clinical evidence